Nimbus Apollo

Nimbus Apollo, Inc. researches and develops drugs for the treatment of non-alcoholic steatohepatitis (NASH). This includes the leading candidate drug NDI-010976 for the treatment of NASH and potentially hepatocellular carcinoma (HCC), as well as ACC inhibitors and other preclinical ACC inhibitors.